crexavibart

Crexavibart (BMS-986413; also known as C144-LS) is a fully human recombinant monoclonal antibody of the IgG1λ2 subtype that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein. It was developed by Bristol Myers Squibb in partnership with Rockefeller University for the treatment of COVID-19. The antibody binds to a specific epitope on the spike protein RBD and neutralizes SARS-CoV-2 by preventing viral entry into host cells. Crexavibart was engineered with Fc modifications to extend its half-life in humans. It has been evaluated both alone and in combination with another monoclonal antibody (BMS-986414/C135-LS) for outpatient treatment of mild-to-moderate COVID-19[1][3][4]. Clinical trials have shown it is safe but did not demonstrate significant efficacy at treating COVID-19 in low-risk outpatients when administered subcutaneously[1][7].

Other names

crexavibartBMS-986413BMS986413BMS 986413C144-LSC-144-LSC 144-LS